Managing Risk And Development In A Growing Neuroscience Portfolio With AbbVie's Sean Kelley
Managing Risk And Development In A Growing Neuroscience Portfolio With AbbVie's Sean Kelley
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Sean Kelley, Vice President for neuroscience and toxins, Portfolio Strategy and Program Leadership at AbbVie, talks through the development factors that determine whether a promising discovery becomes a medicine that reaches patients. Sean shares details about his neuroscience portfolio strategy at AbbVie, and how biomarkers in clinical development, plus dosing and formulation, can matter as
AI 伴隨問答
針對這篇報導有疑問?可直接點選快捷問題或向 AI 追問背景脈絡與技術細節:
Podcast 專家音訊節目
收錄於 888news Podcast 智庫專區,包含精華摘要與上市公司即時行情
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Sean Kelley, Vice President for neuroscience and toxins, Portfolio Strategy and Program Leadership at AbbVie, talks through the development factors that determine whether a promising discovery becomes a medicine that reaches patients. Sean shares details about his neuroscience portfolio strategy at AbbVie, and how biomarkers in clinical development, plus dosing and formulation, can matter as much as the molecule itself. He also discusses partnering in China, and the potential for psychedelics in treating psychiatric disorders, including bretisilocin, AbbVie's first psychedelic clinical program. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/